The following are selected life science industry transactions and financings that were executed by senior members of the Firm.

Alteon Acted as advisor to Alteon, a cardiovascular biotechnology company in its merger with HaptoGuard, a privately-held biotechnology company.

Baxter Acted as advisor to Baxter in its spinoff of Allegiance, a medical products manufacturer and distributor.

Bayer AG Acted as advisor to Bayer Corporation in the sale of ChemDesign Corporation, a fine chemical company, to Chestnut Investments LLC.

Boston Scientific Acted as advisor to Boston Scientific in its $1.1 billion acquisition of Target Therapeutics a maker of implantable neurovascular devices.

Bristol-Myers Squibb Acted as advisor to Bristol-Myers Squibb in its partial acquisition of ImClone Systems and its partnering of Erbitux, an oncology product

Caliper Life Sciences Acted as advisor to Caliper Life Sciences, the leading microfluidics company, in its acquisition of NovaScreen, a life science services company.

Chirex Co-managed the $87 million IPO of this pharmaceutical and intermediates company.

Genzyme Corporation Acted as advisor to Genzyme Corporation in the sale of its Genzyme Pharmaceutical Ingredients Business in Switzerland to International Chemical Investors Group (ICIG).

Leiner Health Products Acted as advisor to AEA Investors, majority shareholder of Leiner in the sale of the private label vitamin and supplement producer to North Castle Partners in a $300 million leveraged recapitalization.

LKC Technologies Acted as placement agent for private placement of securities for this retinal diagnostics company.

Luminex Co-managed the $85 million IPO of this developer of bioassays for the life science industry.

Merck KGaA Acted as advisor to Merck KGaA in its acquisition of the 51% of VWR Scientific, a distributor of laboratory products and supplies, from the public for $575 million.

Nanogen Co-managed the $43 million IPO of this developer of microarray diagnostic testing systems.

Nexell Therapeutics Acted as private placement agent for a $63 million offering of convertible notes backed by Baxter.

NPS Pharmaceuticals Acted as advisor to NPS Pharmaceuticals in its outlicensing of Gattex, a Phase 3 gastrointestinal product to Nycomed for $35 million upfront and $500 million in milestone payments.

Nutrition 21 Acted as co-placement agent in $10 million PIPE financing for Nutrition 21, a supplier of nutritional supplements.

ÖMV Acted as advisor in the sale of ÖMV's fine chemical division, Chemie Linz, located in Austria, to DSM for 2.2 billion schillings

Paratek Pharmaceuticals Acted as advisor to Paratek with regard to a review of its strategic and financial alternatives

Perkin-Elmer Corporation Acted as advisor to the Perkin-Elmer Corporation in the sale of PerSeptive Biosystems GmbH-Hamburg to a subsidiary of SKW Trostberg AG.

Pharmacia & Upjohn Acted as advisor to Pharmacia & Upjohn in the renegotiation of its licensing agreement with Miravant Medical Technologies relating to its ophthalmology compounds.

Phyto-Source L.P. Advised the shareholders of Phyto-Source, a leading supplier of phytosterols, in the sale of the business to Cognis.

Proquest Acted as co-lead placement agent for Proquest, an oncology-focused venture capital fund.

Regeneration Technologies Co-managed the $75 million IPO of this producer of orthopedic products using allograft tissue .

Sanofi Acted as advisor to Sanofi in the sale of its Parental Products business to Abbott Laboratories for $200 million.

Schering AG Acted as advisor to Schering in the defense of a hostile offer from Merck KGaA and subsequent sale to Bayer fro $20.5 billion.

Schick Technologies Acted as advisor to Schick Technologies in the sale of the digital dental radiography company to Sirona Dental.

SmithKline Beecham Acted as advisor to SmithKline Beecham in the acquisition of Block Drug, a consumer products company, for $1.2 billion.

Synthon Chiragenics Acted as advisor to Synthon Chiragenics in the sale of its Fine Chemicals business and the license of certain technology rights to Avecia Ltd.

Teva Pharmaceutical Acted as advisor to Teva Pharmaceutical in its acquisition of generic drug maker Biocraft Laboratories for $356 million.

Thoratec Acted as advisor to Thoratec in its acquisition of Thermo Cardiosystems, a maker of cardiovascular devices, for 460 million.

Versicor Acted as advisor to Versicor in its merger with Biosearch Italia in a $261 million transaction to form Vicuron Pharmaceuticals, an anti-infectives company.